Karyopharm Therapeutics | KPTI - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Abbott USD 68M 26M 2026-03
Amgen USD 657M 4M 2026-03
AstraZeneca USD 484M 181M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Bristol-Myers Squibb USD 411M 21M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
GlaxoSmithKline GBP 167M 21M 2026-03
Incyte USD 569K 13K 2026-03
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Merck USD 479M 67M 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Novartis USD 343M 39M 2026-03
Novartis USD 281M 8M 2025-09
Pfizer USD 671M 40M 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Takeda JPY 43.65B 79.98B 2026-03
Tectonic Therapeutic USD 246.58M 246.56M 2026-03
TG Therapeutics USD 7.67M 1.13M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Xencor USD 4.7M 2.65M 2026-03